COMMUNIQUÉS West-GlobeNewswire

Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access
26/05/2026
- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - - The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation [...]
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
26/05/2026
Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 million Funding award milestone follows Daré's announcement last week of the initiation of its [...]
Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions
26/05/2026
RUTHERFORD, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel [...]
Progyny, Inc. Announces Share Repurchase Program
26/05/2026
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that its Board of Directors has approved a share repurchase [...]
Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer
26/05/2026
Key milestone positions ART6043 as the most advanced Pol-theta inhibitor in clinical development; the potentially first-in-class program is supported by U.S. FDA Fast Track designation CAMBRIDGE, United Kingdom and NEW [...]
VVT Med Announces First Patients Treated with VVT’s ScleroSafe™ System in Italy
26/05/2026
Leading Italian Vein Specialist Dr. Luca Palombi and His Team Successfully Treat First Patients in Italy Using the ScleroSafe™ System VANCOUVER, BC, May 26, 2026 (GLOBE NEWSWIRE) -- VVT Med Inc. (TSXV: VVTM) ("VVT Med" [...]
Annovis Bio Regains NYSE Listing Compliance
26/05/2026
MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Kraig Biocraft Laboratories Smashes Production Targets as New Spider Silk Batch Surges Past Expectations
26/05/2026
Company Reports Record Early Production Results, Exceeding Yield Targets by 20% ANN ARBOR, Mich., May 26, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig' [...]
J-Star Holding Subsidiary Receives Central Bank of Taiwan Authorization to Initiate $60 Million Sovereign-Backed Financing Framework through Designated Banks for U.S. Solid-State Battery Expansion ($122.5 Million Project)
26/05/2026
Funding framework supports development of a US$122.5 million advanced battery manufacturing facility in Baytown, Texas under YMA(TX) INC. TAICHUNG CITY, Taiwan, May 26, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd [...]
Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases
26/05/2026
Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making reducing healthcare costs by 40% Presentation receives blue-ribbon recognition at the ISPOR Annual Meeting, the premier [...]
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
26/05/2026
Independent DSMB has identified no safety concerns, to date, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor Sixth consecutive positive DSMB recommendation [...]
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
26/05/2026
- Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen resulted in a robust and statistically [...]
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
26/05/2026
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy) data in adults with relapsing forms of [...]
LENZ Therapeutics to Participate in Upcoming Investor Conferences
26/05/2026
SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44 [...]
New study finds over a third of young men at risk of gambling related harm; fathers disproportionately affected
26/05/2026
VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Facing economic and financial pressure, new research shows that young men and fathers are at significantly higher risk of problem gambling. This may be [...]
Curevo to be Acquired by Lilly to Advance Next-Generation Shingles Prevention
26/05/2026
Curevo’s lead asset, amezosvatein, is a Phase 3-ready shingles vaccine with potential to increase vaccination rates by delivering improved tolerability versus approved products SEATTLE, May 26, 2026 (GLOBE NEWSWIRE) -- [...]
Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies New York Healthcare Conference 2026
26/05/2026
Tokyo, Japan and Cambridge, UK, 26 May 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces its President & CEO, Chris Cargill, will participate in a ‘Fireside Chat’ at the Jefferies New [...]
Editas Medicine Announces Proposed Public Offering
26/05/2026
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced [...]
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
26/05/2026
– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients – – Results [...]

Pages